Last reviewed · How we verify
Insulin degludec injection, RD15003 — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Insulin degludec injection, RD15003 (Insulin degludec injection, RD15003) — Sunshine Lake Pharma Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Insulin degludec injection, RD15003 TARGET | Insulin degludec injection, RD15003 | Sunshine Lake Pharma Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Insulin degludec injection, RD15003 CI watch — RSS
- Insulin degludec injection, RD15003 CI watch — Atom
- Insulin degludec injection, RD15003 CI watch — JSON
- Insulin degludec injection, RD15003 alone — RSS
Cite this brief
Drug Landscape (2026). Insulin degludec injection, RD15003 — Competitive Intelligence Brief. https://druglandscape.com/ci/insulin-degludec-injection-rd15003. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab